文献速递血液净化与透析肾移植

肾移植受者、血液透析患者、血液恶性肿瘤患者及健康对照者的疲劳、焦虑、抑郁与生活质量比较

Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

该横断面队列研究纳入168例受试者,包括血液透析患者、肾移植受者、接受化疗或处于缓解期的血液恶性肿瘤患者及健康对照,使用SF-36、CIS和HADS问卷评估疲劳、焦虑、抑郁与生活质量。结果显示血液透析和化疗患者严重疲劳及抑郁比例最高、生活质量最低,肾移植受者优于透析患者但总体生活质量仍低于健康对照。

要点

  • 血液透析患者严重疲劳比例53.3%,高于肾移植受者的33.3%和健康对照的12.1%。
  • 血液透析患者抑郁比例33.3%,肾移植受者16.7%,健康对照8.6%,组间差异P=0.066。
  • 肾移植受者报告最大的正向健康变化(+27%,P<0.001),但总体生活质量仍低于健康对照。

核心结论

  • 疲劳和抑郁在血液透析患者中常见,导致其生活质量低,与接受化疗的血液恶性肿瘤患者相当。
  • 肾移植受者情况较好,评分与缓解期血液恶性肿瘤患者相似,但生活质量仍低于健康对照。

研究设计与样本

  • 横断面队列研究,共纳入168例患者,包括血液透析患者、肾移植受者、接受化疗或处于缓解期的血液恶性肿瘤患者及健康对照。
  • 所有参与者完成36项健康相关生活质量简表(SF-36)、个体强度检查表(CIS)和医院焦虑抑郁量表(HADS)问卷。

主要发现

  • 血液透析患者和接受化疗的血液恶性肿瘤患者严重疲劳比例分别为53.3%和50%,高于肾移植受者的33.3%、缓解期血液恶性肿瘤患者的23.3%和健康对照的12.1%(P<0.001)。
  • 焦虑率组间无显著差异。
  • 血液透析患者和接受化疗的血液恶性肿瘤患者最可能抑郁(33.3%和25%),肾移植受者为16.7%,缓解期血液恶性肿瘤患者为20%,健康对照为8.6%(P=0.066)。
  • 肾移植受者报告最大的正向健康变化(+27%,P<0.001),但总体生活质量仍低于健康对照,与缓解期血液恶性肿瘤患者相当。
  • 血液透析和化疗患者报告最低的生活质量评分。

临床怎么用

  • 应关注血液透析患者的疲劳和抑郁,其生活质量与接受化疗的血液恶性肿瘤患者相当。
  • 肾移植受者生活质量优于透析患者但仍低于健康对照,需持续评估和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of haemodialysis (HD) and kidney transplantation on quality of life (QoL) is often underestimated due to a lack of comparative studies with other patient groups. METHODS: We conducted a cross-sectional cohort study in 168 patients including HD patients, kidney transplant recipients (KTR), patients with a haematological malignancy either receiving chemotherapy or in remission and healthy controls. All participants completed the 36-item short form survey of health-related quality of life, the Checklist Individual Strength and the Hospital Anxiety and Depression Scale questionnaire. RESULTS: HD patients and haematological patients undergoing chemotherapy were more frequently severely fatigued (53.3% and 50% of cases) compared with KTR (33.3%), haematological patients in remission (23.3%) and healthy controls (12.1%, P < 0.001). There were no significant differences in anxiety rates. HD patients and haematological patients undergoing chemotherapy were most likely to be depressed (33.3% and 25%), compared with 16.7% of KTR, 20% of haematological patients in remission and 8.6% of healthy controls (P = 0.066). KTR reported the largest positive health change (+27%, P < 0.001), but still had a lower overall QoL than healthy controls, comparable to haematological patients in remission. HD and chemotherapy patients reported the lowest QoL scores. CONCLUSIONS: Fatigue and depression are common in HD patients, resulting in a low QoL, comparable to haematological patients receiving chemotherapy. KTR do better, with scores similar to patients with a haematological malignancy in remission, but still have a lower QoL than healthy controls.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. van Sandwijk MS, Al Arashi D, van de Hare FM, et al. Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. Nephrol Dial Transplant. 2019. PMID: 29726909. doi:10.1093/ndt/gfy103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。